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Summary The mammalian natriuretic peptide family consists of atrial (ANP), brain [B-type;
BNP] and C-type natriuretic peptide (CNP) and three receptors, natriuretic receptors-A (NPR-
A), -B (NPR-B) and -C (NPR-C). Both ANP and BNP are abundantly expressed in the heart and
are secreted mainly from the atria and ventricles, respectively. By contrast, CNP is mainly
expressed in the central nervous system, bone and vasculature. Plasma concentrations of both
ANP and BNP are elevated in patients with cardiovascular disease, though the magnitude of the
increase in BNP is usually greater than the increase in ANP. This makes BNP is a clinically useful
diagnostic marker for several pathophysiological conditions, including heart failure, ventricular
remodeling and pulmonary hypertension, among others. Recent studies have shown that in
addition to BNP-32, proBNP-108 also circulates in human plasma and that levels of both forms are
increased in heart failure. Furthermore, proBNP-108 is O-glycosylated and circulates at higher
levels in patients with severe heart failure. In this review we discuss recent progress in our
understanding of the biochemistry, molecular biology and clinical relevance of the natriuretic
peptide system.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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ntroduction
he natriuretic peptide system consists of three distinct
ndogenous peptides: atrial natriuretic peptide (ANP), brain
or B-type) natriuretic peptide (BNP) and C-type natriuretic
eptide (CNP), as well as three receptors: natriuretic pep-
ide receptor-A (NPR-A or guanynyl cyclase-A), natriuretic
eptide receptor-B (NPR-B or guanynyl cyclase-B) and natri-
retic peptide receptor-C (NPR-C or clearance receptor).
ecent advances suggest that through its pleiotropic effects,
his system plays key roles in the regulation of blood pressure
nd body ﬂuid volume. In this review, we discuss the cur-
ent understanding of the biochemistry, molecular biology
nd clinical relevance of natriuretic peptides.
tructures of the genes and peptides
NP
irsch reported in 1956 that mammalian atrial myocytes
ontain granules with morphologies similar to the granules
ound in endocrine cells [1]. However, the signiﬁcance of
hese granules was not recognized until 1981, when de
old et al. reported that intravenous injection of crude
yocardial extract induces a natriuretic effect in rats [2],
uggesting the heart contains a natriuretic hormone. These
ndings ultimately led to the identiﬁcation of the complete
mino acid sequence of ANP in mammalian atrial tissue
3]. Subsequent studies showed that ANP is synthesized and
ecreted from the heart into the circulation as a cardiac
ormone in response to atrial stretch. The major molecular
orm of circulating ANP is a 28-amino acid peptide (-ANP)
ith a ring structure formed by an intramolecular disulﬁde
inkage (Fig. 1).
ANP gene contains three exons. Exon 1 encodes the 5′-
ntranslated region, a 25-amino acid signal peptide and the
rst 16 amino acids of proANP. Exon 2 encodes most of the
roANP sequence, and exon 3 encodes the terminal tyrosine
nd 3′-untranslated region (Fig. 2). ANP mRNA is translated
o 151-amino acid preproANP. Thereafter, the 25-amino acid
ignal peptide is removed, yielding 126-amino acid proANP
-ANP) [4]. Because the tissue molecular form of ANP in
he atrium and ventricle is proANP, it is presumed that the
roteolytic conversion of proANP to ANP occurs during secre-
t
a
a
t
Bigure 1 Structures of the human natriuretic peptide family
embers: (A) ANP; (B) BNP; and (C) CNP. Identical amino acids
equences are indicated by yellow shading.
ion. Consistent with that notion, a recent study showed
hat a transmembrane enzyme, corin, cleaves proANP into
-ANP and N-terminal proANP [5]. Interestingly, human -
NP, the antiparallel dimer of -ANP, is also isolated from
he human failing heart, and levels of -ANP are increased
n the myocardium [6] and plasma [7] in cases of severe heart
ailure (Fig. 2).
NP
NP was ﬁrst isolated from porcine brain extracts in 1988 by
udoh et al. [8]. Soon after its discovery, however, the high-
st concentrations of BNP were shown to be in the heart,
here it acts as a cardiac hormone [9]. BNP peptides and
DNA clones from a variety of species have now been isolated
nd sequenced. The predominant circulating form of BNP is
26-, 45- and 32-amino acid peptide in pig, rat and human,
espectively [10]. Thus, whereas the structure of ANP is rel-
tively well conserved among species, the structure of BNP
iffers. The mature active molecular form of human BNP
s BNP-32 (Fig. 1). Like ANP gene, BNP gene contains three
xons (Fig. 3). Exon 1 encodes a 26-amino acid signal pep-
ide and the ﬁrst 15 amino acids of proBNP. Exon 2 encodes
ost of the proBNP sequence, and exon 3 encodes the ter-
inal tyrosine and the 3′-untranslated region. BNP mRNA isranslated to 134-amino acid preproBNP, after which the 26-
mino acid signal peptide is removed, yielding 108-amino
cid proBNP-108. In contrast to ANP, atrial and ventricular
issue contain two molecular forms of BNP: proBNP-108 and
NP-32. BNP-32 is dominant (∼60%) in atrial tissue, while
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pFigure 2 Structure of the gene and biosynthe
proBNP-108 is dominant (∼60%) in ventricular tissue [11].
It is thought that cleavage of proBNP into BNP-32 and N-
terminal proBNP-76 occurs in the trans-Golgi network [12]
and that BNP-32 and N-terminal proBNP are then released
into the circulation via a constitutive pathway. However,
recent studies have shown that proBNP-108 is also present
in human plasma and that the proBNP-108/BNP-32 ratio is
increased in cases of severe heart failure [11]. We discuss
the molecular forms of plasma BNP in detail in ‘‘Molecular
complexity of plasma BNP — increase of proBNP-108 in heart
failure’’ and ‘‘A new hypothesis of processing of proBNP’’
sections.CNP
CNP was ﬁrst isolated from porcine brain in 1990 [13]. Com-
posed of 22 amino acids, the ring structure of CNP is highly
t
3
1
n
p
Figure 3 Structure of the gene and biosynthetic pathway of human ANP. mRNA: messenger RNA.
omologous with those of ANP and BNP, but CNP uniquely
acks the carboxy-terminal extension (Fig. 1). Based on
olecular cloning of CNP cDNA and the genes from various
pecies, it has been predicted that the structure of CNP is
dentical among species and is the most highly conserved in
he natriuretic peptide family. CNP-53, which has an amino-
erminal extension of 31 amino acids, is a second endoge-
ous form of CNP. Also ﬁrst isolated from the porcine brain,
NP-53 has now been identiﬁed in both human and rat brain.
Like the other natriuretic peptide genes, CNP gene con-
ains three exons. Exon 1 encodes a 23-amino acid signal
eptide and the ﬁrst 7 amino acids of proCNP. Exon 2 encodes
he rest of the proCNP sequence, and exon 3 encodes the
′ untranslated region (Fig. 4). PreproCNP is comprised of
26 amino acids, the ﬁrst 23 of which are cleaved as a sig-
al peptide. The resulting 103-amino acid proCNP is further
rocessed to CNP-53 and/or CNP, the potencies of which
athway of human BNP. mRNA: messenger RNA.
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re essentially the same. Furin is thought to cleave proCNP
nto CNP-53 [14], whereas PC2 and/or PC1/3 are thought
o cleave proCNP into CNP. CNP-53 is generally the major
ndogenous tissue molecular form [15].
issue distribution and gene expression
NP
NP is abundantly expressed in the heart, such that tissue
evels of ANP are 250—1000-fold higher in atrium than in
entricle. The atrium is the major site of ANP synthesis,
nd ANP mRNA levels are considerably higher in the atria
han in the ventricles. High levels of both ANP mRNA and
NP are found in the ventricles of neonatal rats, but these
evels rapidly decline in parallel with the change in cardiac
ontractile protein isoforms that occurs after birth [4]. As
result, healthy adult ventricular tissue actually produces
ittle ANP. However, ventricular ANP expression is re-induced
n the hypertrophied and failing heart, making the ventricle
substantial source of circulating ANP in cases of severe
eart failure [16].
ANP mRNA has also been detected in a variety of extrac-
rdiac tissues, including the hypothalamus, pituitary gland
nd lung [17], but the extracardiac expression is generally
eak. Within the central nervous system, the highest
NP concentrations are in the hypothalamus and septum.
he major molecular forms of ANP as a neuropeptide are
-ANP(4—18) and -ANP(5—28) [18]. Thus, the molecular
orms of the ANP neuropeptide differ from those of the
NP cardiac peptide. Finally, urodilatin, an N-terminal
-amino acid-extended form of -ANP derived from -ANP,
as identiﬁed in urine. Its site of production is the kidney
19].NP
oncentrations of BNP and its mRNA are much lower in the
uman cardiac ventricle than in the atrium, but the total
e
e
E
f
gathway of human CNP. mRNA: messenger RNA.
ontent of BNP and its mRNA in the ventricle accounts for
0% and 70% of that in the whole heart, respectively [20]. A
linical study also showed that plasma BNP levels are higher
n the anterior interventricular vein and the coronary sinus
han in the aortic root, suggesting BNP is a cardiac hormone
hat is predominantly synthesized in and secreted from the
entricle [21]. In addition, no appreciable amount of BNP has
een detected in the rat or human brain, suggesting that the
issue distribution of BNP differs among species.
ProBNP-108 is most likely cleaved by a processing enzyme
o BNP-32 and NT-proBNP-76 as it is secreted [10]. Levels of
yocardial BNP mRNA and circulating BNP and NT-proBNP-
6 are obviously increased as compared with those of ANP
n patients with congestive heart failure, which suggests
NP functions as an emergency defense against ventricular
verload in disease states.
One of the characteristic features of BNP mRNA that sets
t apart from ANP mRNA is a conserved sequence consist-
ng of repeated AUUUA units in the 3′ untranslated region
Fig. 3). The presence of this sequence accelerates the
egradation of BNP mRNA in a manner similar to that seen
ith lymphokine genes and oncogenes [22]. Thus, BNP gene
xpression is regulated differently from ANP gene expres-
ion and is thought to dynamically change, depending on
he physiological and pathophysiological conditions.
NP
NP is distributed throughout the brain in rats and humans,
nd a substantial amount is present in pituitary gland in
at. Consequently, CNP was initially thought to act as a
europeptide [22]; however, subsequent studies showed
hat CNP is also synthesized in kidney, bone, blood cells,
lood vessels and heart [23]. For example, cultured vascular
ndothelial cells (ECs) reportedly show signiﬁcant CNP gene
xpression and peptide secretion [24]. CNP secretion from
Cs is stimulated by such cytokines as transforming growth
actor, tumor necrosis factor, interleukin-1, basic ﬁbroblast
rowth factor, and lipopolysaccharide. This suggests CNP
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may be active in the vascular wall under various pathological
conditions [25]. On the other hand, initial studies failed to
detect CNP mRNA in human or rat heart, and the low levels
of CNP immunoreactivity detected in pig and human hearts
were thought to reﬂect cross-reactivity with ANP or products
from coronary arterial ECs [26]. Subsequent immunohis-
tochemical and reverse transcription polymerase chain
reaction analyses conﬁrmed the presence of CNP and its
mRNA in both the atrium and ventricle, and a recent in vitro
study veriﬁed that a signiﬁcant amount of CNP is expressed
in and secreted from cultured rat cardiac ﬁbroblasts, but
not myocytes, indicating a cardiac expression proﬁle that is
distinctly different than those of ANP and BNP [27].
Molecular mechanism regulating natriuretic
peptide gene expression
Transcriptional regulation of ANP gene expression
Studies using transgenic mice carrying a 500-bp segment
of the 5′ ﬂanking region (5′-FR) of the human ANP gene
fused to a gene encoding SV40 large T antigen, a 2.4-kbp
5′-FR segment of human ANP gene fused to the chloram-
phenicol acetyltransferase gene, or a 638-bp or 3-kbp 5′-FR
segment of the rat ANP gene fused to the luciferase gene
have shown that the proximal 5′-FR of the ANP gene is
sufﬁcient to recapitulate the spatial and temporal expres-
sion of the endogenous ANP gene, and that the region
contains sequences important for the regulation of ANP
gene expression in the heart [28—30]. Indeed, expres-
sion of a reporter gene driven by the proximal 5′-FR of
the ANP gene in atrial or ventricular cardiac myocytes
at different developmental stages showed that the region
confers proper spatial and temporal activity to the ANP
promoter [31,32]. The proximal 5′-FR of the ANP gene
contains multiple transcription factor-binding sites, includ-
ing two CArG boxes, two NKEs, three TBEs, two GATA
sites, an A/T-rich element and a phenylephrine-responsive
element (PERE), to which the transcriptional factors SRF,
NKX2.5, Tbx5, GATA4/6, MEF2C and Zfp260 have been shown
to bind [33,34]. These transcriptional factor-binding ele-
ments contribute singly and cooperatively to the basal and
inducible activation of ANP promoter activity in cardiac cells
[33,34]. In addition, neuron-restrictive silencer element
(NRSE), hypoxia-response element (HRE) and glucocorticoid
responsive element (GRE), which are located outside the
proximal promoter, also reportedly mediate inducible ANP
gene transcription [33,36]. In that regard, differences in
the expression pattern of the proximal 5′-FR of the ANP
gene and the intact endogenous ANP gene highlight the
importance of regulatory elements outside the proximal
5′-FR [33]. It also should be noted that the ANP gene is
located 8 kbp and 12 kbp downstream of the BNP gene on
the same chromosome in humans and mice, respectively
(human, chromosome 1; mouse, chromosome 4) [37,38].Transcriptional regulation of BNP gene expression
The 5′-FR of the BNP gene has also been studied so as
to better understand the regulatory mechanisms govern-
ing the gene’s cardiac-speciﬁc and inducible expression. A
s
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tudy using transgenic mice carrying a 5′-FR segment of the
uman BNP gene extending from −1818 to +100, or from
408 to +100, coupled to a luciferase gene (−1818hBNPluc
nd −400hBNPluc, respectively) showed that the proximal
egion of the human BNP promoter is sufﬁcient to medi-
te ventricle-speciﬁc expression [39]. The luciferase activity
f −1818hBNPluc was also greater in ventricular myocytes
han in atrial myocytes [40]. In addition, deletion analysis
howed that the region extending from −127 to −40 of the
uman BNP 5′-FR confers cardiac-speciﬁc expression [40].
his proximal region of the human BNP promoter contains
otential GATA, M-CAT and AP-1/CRE-like elements, which
re conserved among humans, rats and mice [41].
All three of the aforementioned elements are known to
egulate cardiac-speciﬁc gene expression, and have been
hown to mediate both basal and inducible BNP gene expres-
ion [41]. Other sites located in relatively distal regions of
he human BNP 5′-FR, including NRSE (−552), shear stress-
esponsive elements [SSRE] (−652, −641 and 161), thyroid
ormone-responsive element (TRE) (−1000) and the nuclear
actor of activated T-cells (NF-AT) binding site (−927), have
lso been shown to participate in inducible activation of the
uman BNP promoter [41,42]. Among these elements, the
ranscriptional repressor element NRSE, which is located at
552 in the human BNP promoter and is conserved in the rat
nd mouse BNP promoters, represses basal BNP promoter
ctivity and mediates hypertrophic signaling evoked with
xtracellular matrix [43]. A transcriptional repressor, neu-
on restrictive-silencer factor (NRSF, also named as REST),
inds to NRSE, thereby repressing promoter activity. Inter-
stingly, NRSE is also located in the 3′ untranslated region
f the ANP gene and is involved in basal and endothelin-
-inducible activation of human ANP transcription [35].
oreover, cardiac-restricted inactivation of NRSF through
verexpression of a dominant-negative NRSF driven by the
ardiac-speciﬁc a-MHC promoter leads to up-regulation of
entricular ANP and BNP gene expression, cardiomyopathy
nd sudden death, which conﬁrms the importance of NRSF in
he regulation of cardiac gene expression and cardiac func-
ion [36]. Although BNP gene expression is reportedly under
he control of SRF, as is the case with ANP gene expression, a
unctional CArG box had not been identiﬁed in the proximal
′-FR of the BNP gene [44]. However, we recently identi-
ed a conserved and functional CArG box in the BNP 5′-FR,
nd showed that Rho- and actin dynamics-dependent signal-
ng activates BNP gene expression through this element by
nducing translocation of a novel SRF co-factor, myocardin-
elated transcription factor (MRTF)-A (also named as MAL or
KL1) [45,46].
ranscriptional regulation of CNP gene expression
ranscriptional regulation of CNP has received much less
ttention than that of ANP and BNP. It is known, how-
ver, that two GC-rich elements in the CNP promoter
lay an important role in regulating CNP gene expres-
ion [47]. TSC22D1, a leucine zipper protein, and STK16
TSF-1), a protein possessing both DNA-binding ability and
erine-threonine kinase activity, have been identiﬁed as
ranscription factors that bind to the GC-rich element
48,49].
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NP and BNP as diagnostic markers of
ardiovascular disease
lasma levels of ANP and BNP are increased under
uch pathological conditions as heart failure, myocardial
nfarction, hypertension, left ventricular hypertrophy and
ulmonary hypertension.
eart failure
nitial studies demonstrated that plasma ANP levels increase
n proportion to the severity of symptomatic congestive
eart failure [50]. Similarly, levels of both ANP and BNP
ncrease and their secretion proﬁles vary according to the
nderlying cardiac condition in patients with severe heart
ailure [51]. Several studies have also shown that plasma ANP
evels are signiﬁcantly elevated in asymptomatic patients
ith left ventricular dysfunction. Conversely, the severity of
eart failure has been evaluated based on plasma BNP lev-
ls, which closely correlate with NYHA functional class and
emodynamics [21]. In addition, plasma ANP levels increase
n response to increases in right and/or left atrial pres-
ure, while increases in BNP reﬂect the degree of ventricular
verload. Plasma BNP levels are also useful for identify-
ng patients with asymptomatic left ventricular dysfunction,
nd several investigators have found that they can serve as
iagnostic markers of left ventricular systolic dysfunction
oth in the general population and in patients with cardio-
ascular disease [52]. Furthermore, low BNP levels can be
sed to rule out congestive heart failure in symptomatic
ndividuals with higher negative predictive values. In the
rgent care setting, rapid measurement of BNP values is
seful for establishing or excluding a diagnosis of conges-
ive heart failure in patients with acute dyspnea [53]. Thus,
easuring BNP levels is useful not only for evaluating the
everity of heart failure, but also for excluding and screening
or left ventricular dysfunction and heart failure. For these
easons, authoritative guidelines on the clinical diagnosis
nd management of heart failure recommend measuring BNP
54—56].
cute myocardial infarction
lasma ANP levels are already elevated by the time patients
ith acute myocardial infarction are admitted to hospi-
al and decrease thereafter. By contrast, although plasma
NP levels are signiﬁcantly elevated at admission, they do
ot peak until 12—24 h after the onset of infarction; they
hen decline and peak once again 5—7 days later [57]. Fur-
hermore, despite a gradual decline, BNP levels remain
igniﬁcantly elevated during the chronic phase, reﬂect-
ng any permanent impairment of left ventricular function
nd/or remodeling that occurs. BNP levels return to normal
r near normal in patients without left ventricular remod-
ling after successful early coronary reperfusion [58]. The
eight of the second peak during the acute phase serves as a
aluable index of left ventricular remodeling in patients with
cute myocardial infarction [59], as myocardial hypoxia,
ntracellular acidosis and myocardial stretch all contribute
e
e
a
p
h
s
aT. Nishikimi et al.
o the increase in natriuretic peptide levels during ventric-
lar remodeling [60].
ypertension and left ventricular hypertrophy
everal studies have shown that plasma ANP and BNP levels
re higher in patients with hypertension than in normoten-
ive individuals [61], and are higher in hypertensive patients
ith left ventricular hypertrophy than in those without left
entricular hypertrophy [62]. In addition, BNP levels are
igniﬁcantly higher in patients with left ventricular concen-
ric hypertrophy than in those with eccentric hypertrophy
r concentric remodeling, or in patients with essential
ypertension but a normal left ventricular structure [63].
ntihypertensive therapy that reduces blood pressure leads
o a decline in BNP levels and a reduction in left ventricular
ass [64]. Measurement of BNP is also useful for detection
he patients with left ventricular hypertrophy in the general
opulation [65].
ulmonary hypertension
lasma ANP and BNP levels are elevated in patients with
ight ventricular overload, such as that caused by pul-
onary hypertension, or right ventricular volume overload,
uch as that caused by an atrial septal defect. Inter-
stingly, ANP is dominant in atrial septal defects [66],
hereas BNP is dominant in pulmonary hypertension [67];
ut when pulmonary hypertension accompanies an atrial
eptal defect, BNP is dominant. ANP and BNP levels correlate
ith mean pulmonary arterial pressure, right atrial pressure,
ight ventricular end-diastolic pressure and total pulmonary
esistance in patients with pulmonary hypertension [67].
NP and BNP levels decline together with a reduction in
otal pulmonary resistance after long-term therapy with
rostaglandin derivatives [68]. Plasma BNP levels are also
levated in patients with acute pulmonary embolism. In
hese patients, elevated BNP is associated with right ventric-
lar overload as well as increased mortality. Thus, pressure
verload in the right atrium and ventricle stimulates ANP
nd BNP secretion independently of etiology, and plasma
evels of these peptides are good indices of the severity and
ffects of treatment in patients with right ventricular over-
oad. These results suugest that the measurement of BNP is
useful means assessing disease severity, the effect of drug
reatment, and the prognosis of patients with cardiovascular
isease.
olecular complexity of BNP in plasma —
ncreased proBNP-108 in heart failure
roBNP-108 is thought to be cleaved to BNP-32 and N-
erminal proBNP-76 in an equimolar fashion by a processing
nzyme as it is secreted from ventricular myocytes. How-
ver, recent studies have shown that, in addition to NP-32
nd NT-proBNP-76, proBNP-108 also circulates in human
lasma and that the level of this peptide is increased in
eart failure [69,70]. What is more, other studies have
hown that the assay kit currently being used for BNP-32
lso recognizes proBNP-108 and that there is a high degree
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Figure 5 Schematic representation of the processing and glycosylation of proBNP in cardiomyocytes. Some of the biosynthesized
proBNP-108 is O-glycosylated within the Golgi apparatus. If O-glycosylation does not occur at Thr-71, proBNP-108 is cleaved to BNP-
NP-3
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N32 and NT-proBNP-76 by furin within the trans-Golgi network. B
If O-glycosylation occurs at Thr-71 of proBNP, glycosylated-pro
glycosylated proBNP-108 is secreted into the circulation.
of cross-reactivity [71], which suggests the BNP level mea-
sured using this assay system is the sum of the BNP-32 and
proBNP-108 levels. We recently showed that both proBNP-
108 and BNP-32 circulate in the plasma of patients with heart
failure and that the proBNP-108/BNP-32 ratios vary greatly,
depending on the patient’s heart failure status [11]. This
ratio is markedly higher in patients with heart failure caused
by ventricular overload, as well as in those with decom-
pensated heart failure, but the ratio is not increased in
patients with atrial overload. In addition, proBNP-108 is a
major molecular form in human ventricular tissue. These
ﬁndings are consistent with the hypothesis that proBNP-108
is the major molecular form of BNP in the ventricle and
that proBNP-108 levels increase in response to ventricular
overload [11].
On the other hand, proBNP-108 does not induce cGMP
production as effectively as BNP-32. In mild to moderate
heart failure, the plasma cGMP level increases in proportion
to the severity of the heart failure, and its level corre-
lates with plasma BNP. In severe heart failure, however,
the increases in cGMP level are attenuated relative to the
disease state, so that the plasma cGMP levels no longer cor-
relate with the BNP levels [72]. Apparently, the increase in
the hormonally less active proBNP-108 that occurs in severe
heart failure results in a relative deﬁciency in natriuretic
peptide.
A new hypothesis of processing of proBNPRecent studies have shown that proBNP-108 is O-
glycosylated and that the degree of glycosylation depends
on heart failure severity [73,74]. The clinical relevance of
proBNP-108 glycosylation remains unclear, however. Vari-
ous stimuli, including pressure overload, volume overload
A
W
I2 and NT-proBNP-76 are then secreted in an equimolar fashion.
108 is not cleaved by the processing enzyme, and uncleaved
nd ischemia, stimulate BNP gene transcription, after which
he transcript is translated in the endoplasmic reticulum
o produce preproBNP. As the protein is processed in the
olgi network, removal of its signal peptide generates
roBNP-108, which can then be posttranslationally glyco-
ylated to varying degrees at several sites in its N-terminal
egion (Ser36, Thr37, Thr44, Thr48, Thr53, Ser58 and Thr71).
he O-glycosylated proBNP-108 is then transported to the
rans-Golgi network, where it is cleaved to BNP-32 and
T-proBNP-76, probably by furin [75]. Both BNP-32 and NT-
roBNP-76 are thought to be secreted via a constitutive
athway without storage in secretory granules.
How glyco-proBNP-108 is secreted without processing
nder conditions of severe heart failure is not fully under-
tood. One recent study has shown that O-glycosylation at
hr-71, which is situated close to the cleavage site, impairs
roBNP-108 processing by furin in HEK293 cells, a cell line
erived from human embryonic kidney cells [76] (Fig. 5).
ecause the effect of O-glycosylation was only evaluated
ith furin in that vitro study, the actions of other poten-
ial processing enzymes are still unknown. Also unknown is
hether similar glycosylation occurs in cardiac myocytes in
oth the atrium and ventricle. Further studies using cardiac
yocytes will be required to elucidate the precise mecha-
ism by which proBNP-108 is processed.
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